Sartorius to acquire UK’s Albumedix for $501.5m

Life science group Sartorius has signed a definitive agreement for the acquisition of complete outstanding shares of UK-based company Albumedix. With the acquisition, Albumedix will become part of the Bioprocess Solutions Division of Sartorius.

Rene Faber member of the Executive Board for the Bioprocess Solutions Division of Sartorius had said that, “Albumedix will be an important addition to Sartorius’ advanced therapy solutions, particularly regarding our cell culture media business, as it will enable us to strengthen our position as a relevant supplier of innovative chemically defined media and critical ancillary materials. This market offers high growth potential due to the increasing regulatory requirements as well as rising demand for the use of recombinant human albumin in near-patient applications. Albumedix will also add important formulation excipients to our vaccine production solutions, allowing us to expand our existing customer relationships and forge new ones”.

Jonas S. Moller, CEO of Albumedix had said that “We are delighted to be joining forces with Sartorius and look forward to accelerating our ambitious growth plans in delivering critical solutions to our global customers. We have been highly impressed with Sartorius’ knowledge and capabilities in the bioprocessing markets, and we are excited to join this purposeful journey. We believe Sartorius will bring tremendous value in strengthening our market reach and broadening our innovation capacity, as well as significantly scaling up our existing platform. We remain focused on our promise of empowering excellence in the life science industry”.

Sartorius will acquire all outstanding shares of Albumedix Ltd. for approximately £415 million

For Future Conferences Visit: https://usa-canada.virtueinsight.com/upcoming-conferences/